How Do You Get Mycoplasma: Causes and Transmission

Mycoplasma spreads through three main routes depending on the species involved: respiratory droplets for Mycoplasma pneumoniae, sexual contact for Mycoplasma genitalium, and direct contact during childbirth for species like Mycoplasma hominis. What makes mycoplasma infections tricky is that people who feel perfectly healthy can carry and spread the bacteria for weeks or months, and the incubation period before symptoms appear runs two to three weeks. Understanding which species you are dealing with changes almost everything about how transmission works and what you can do about it.

Respiratory Spread of Mycoplasma Pneumoniae

M. pneumoniae is the most common pathogen causing respiratory tract infections in its category, and it gets into your body the same way most respiratory infections do: through inhaled droplets from an infected person’s cough, sneeze, or even talking at close range.¹ Once inhaled, the bacterium uses a specialized adhesion protein on its surface called P1 to latch onto cells lining your airways. That attachment step is what kicks off the infection, and without it, the organism cannot establish a foothold.

What sets M. pneumoniae apart from viruses like influenza is the closeness of contact required. You are far more likely to catch it from a family member or a classmate you sit next to every day than from a stranger on a bus. A study of pediatric hospital rooms found that while the bacterium could be detected in air samples taken roughly three meters from an infected patient’s bed, the detection rate at that distance was only about 17%.² At the same time, M. pneumoniae was found at very high concentrations on surfaces and objects in those rooms, suggesting that touching contaminated items and then touching your face is another plausible transmission route. Prolonged or repeated close contact remains the biggest risk factor, which is why outbreaks tend to cluster in households, dormitories, and military barracks rather than spreading rapidly through casual encounters.

How Sexual Transmission Works for Genital Species

Mycoplasma genitalium and Mycoplasma hominis are completely different organisms from M. pneumoniae, and they spread through sexual contact rather than coughing. M. genitalium in particular behaves like a classic sexually transmitted infection. It is detected far more often in sexually active people than in those who have not had sexual contact, it shows up in the partners of infected individuals, and it is especially common among younger adults with multiple partners.³

Men who have sex with men face a particularly high burden of genital mycoplasma infections. In a study of HIV-positive men who have sex with men screened across multiple body sites, M. genitalium was found in about one in ten participants, while M. hominis was detected in roughly 18%. Rectal sites had the highest detection rates for both species, which makes sense given the route of exposure.⁴ This pattern of anatomical-site-specific colonization is important because standard STI screening panels often test only urethral or vaginal samples, potentially missing rectal or oral infections entirely.

M. hominis occupies an in-between space. It is sometimes sexually transmitted, but it also commonly colonizes the genital tract of healthy women without causing symptoms. In a large Korean study of nearly 5,800 asymptomatic individuals, about one in ten women tested positive for urogenital mycoplasma species, though the rate in men was much lower at under 1%.⁵ That high rate of silent colonization means a person can transmit M. hominis to a sexual partner without either person knowing anything was there.

Mother-to-Child Transmission During Birth

Newborns can pick up genital mycoplasma species as they pass through the birth canal. The rates of this vertical transmission are surprisingly high. One study found that 60% of babies born to mothers colonized with M. hominis became colonized themselves.⁶ A separate study confirmed similarly high transmission, with about 68% of newborns born to carrier mothers testing positive. Interestingly, that study found higher colonization rates among babies born to first-time mothers and among male newborns compared to female ones.⁷

Most of the time, colonization in a newborn clears on its own. But in premature infants or those with underdeveloped immune systems, these organisms can contribute to respiratory problems, meningitis, or other complications. The challenge is that because colonization is so common and usually harmless, screening every pregnant woman is not standard practice in most healthcare systems.

The Silent Carrier Problem

One of the most underappreciated aspects of mycoplasma transmission is how many carriers show no symptoms at all. For the respiratory species, a study comparing around 400 healthy children to over 300 children with respiratory symptoms found that M. pneumoniae DNA was present in about 21% of the asymptomatic group and 16% of the symptomatic group. That difference was not statistically meaningful.⁸ In other words, the bacteria were about equally common in kids who felt fine and kids who were sick. Even more striking, longitudinal sampling showed that M. pneumoniae could persist in the upper respiratory tract for up to four months.⁹

For the genital species, the same pattern holds. M. hominis was found in about 8% of asymptomatic women in one cross-sectional study of endocervical swabs.¹⁰ These carriers have no idea they are harboring the organism and can unknowingly pass it along. This is one of the reasons mycoplasma infections keep circulating: you cannot isolate carriers if you cannot tell who they are.

The diagnostic problem compounds this. Both blood-based antibody tests and PCR swabs for M. pneumoniae struggle to distinguish someone who is genuinely infected from someone who is merely carrying the organism asymptomatically. Published carriage rates in healthy children range from under 3% to as high as 56%, depending on the study, the population, and the testing method used.⁹ That enormous range makes it genuinely hard to know how much transmission is happening beneath the radar at any given time.

Where Outbreaks Tend to Start

For M. pneumoniae, outbreaks follow a predictable geography: they start in places where people spend hours together in enclosed spaces. Schools are the most common ignition point, but the real amplification happens at home. A community outbreak investigation found that while the bacterium was circulating in schools, it was household transmission that ultimately drove the scale of the outbreak.¹¹ A child picks it up from a classmate, brings it home, and spends the two-to-three-week incubation period sharing air and surfaces with family members before anyone develops symptoms.

Modeling studies confirm that without any intervention, M. pneumoniae outbreaks can infect a staggering proportion of the population in a closed setting. One dynamic model based on an outbreak in Hangzhou estimated that without control measures, over 95% of exposed individuals would become infected and the outbreak would persist for nearly five months.¹² That level of spread is possible precisely because of the long incubation period combined with the high rate of asymptomatic carriage described earlier.

Network analysis of past outbreaks suggests that caregivers and healthcare workers play an outsized role in spreading the infection within institutional settings. Even when the overall prevalence of active illness among staff is low, their patterns of moving between patients and rooms make them efficient connectors. The most effective intervention strategies are those that reduce the diversity of caregiver-patient interactions, essentially limiting how many different people a single staff member contacts in a day.¹³

The Multi-Year Epidemic Cycle

Unlike most respiratory infections, which follow predictable annual winter surges, M. pneumoniae operates on a longer clock. Major epidemics tend to roll through communities every four to five years, with each wave lasting roughly 12 to 18 months. Data from England and Wales documented this pattern clearly: cyclic epidemics with a mean duration of about 18 months, recurring approximately every four years, layered on top of smaller annual seasonal fluctuations that peak in winter.¹⁴

Danish surveillance data stretching back half a century confirms the pattern and offers an explanation. The multi-year cycle appears to be driven primarily by the waning and rebuilding of population immunity. After a large outbreak, enough people have been infected that the bacterium struggles to find susceptible hosts, and transmission dies down. Over the next several years, immunity fades and newborns who were never exposed grow into school age. Once the pool of susceptible people reaches a critical mass, another epidemic ignites.¹⁵ This means your risk of encountering M. pneumoniae is not constant from year to year. During an off-cycle period, your chances of exposure are much lower, while in a peak year, you may hear about outbreaks in your area.

Co-infections and Why They Matter for Genital Species

If you test positive for M. genitalium, there is a decent chance you are carrying something else too. Among HIV-positive men who have sex with men screened for multiple STIs, about a third had concomitant bacterial infections, with rectal sites being the most common location for co-infection.⁴ A study looking specifically at the overlap between M. genitalium and gonorrhea found that among people infected with chlamydia or gonorrhea, about 28% were also co-infected with M. genitalium. The association with gonorrhea was particularly strong.¹⁶

In heterosexual populations, the co-infection picture is somewhat different but still relevant. Among patients visiting a sexual health clinic in Guangzhou, about one in four had at least one additional STI. M. genitalium was found in roughly 5% of men and 6% of women.¹⁷ The practical takeaway is that if you are diagnosed with one genital mycoplasma species, it is worth asking your provider to screen for other common STIs as well, since the same behaviors that expose you to one tend to expose you to others.

Antibiotic Resistance and Its Effect on Ongoing Spread

M. genitalium has developed significant antibiotic resistance over the past two decades, and this has a direct effect on transmission. When treatment fails to clear an infection, the person remains infectious and continues to pass the bacterium to partners. Resistance to macrolides, the first-line treatment for M. genitalium, is now common in many parts of the world. Fluoroquinolone resistance is growing as well.

A quasi-experimental screening study examined what happens when infections are treated versus left alone. Treatment increased the probability of clearing the infection, but among infections that persisted after treatment, there was no significant difference in fluoroquinolone resistance between those that cleared and those that stuck around. In the untreated group, the picture was different: infections that spontaneously cleared were more likely to be fluoroquinolone-resistant (all of them, in fact), while those that persisted without treatment were less likely to carry resistance.¹⁸ The dynamics are counterintuitive, but the bottom line is that widespread screening and treatment of asymptomatic M. genitalium infection could paradoxically increase resistance in the remaining pool of infections, making future cases harder to treat and extending the chain of transmission.

Can You Catch Mycoplasma from Animals or Contaminated Surfaces

Mycoplasma species are generally considered host-specific, meaning the ones that infect humans tend not to infect other animals and vice versa. Your dog’s respiratory mycoplasma is not the same organism as the one that causes walking pneumonia in people. That said, the host specificity of mycoplasmas is not absolute. There are documented cases of mycoplasma species crossing into hosts outside their normal range, particularly when the recipient has a compromised immune system.¹⁹ For a person with a healthy immune system, catching mycoplasma from a pet or wild animal is not a realistic concern.

Surface transmission is a more nuanced question. As mentioned earlier, M. pneumoniae has been found at high concentrations on objects in hospital rooms occupied by infected patients.² Mycoplasma bacteria lack a cell wall, which makes them fragile compared to many other pathogens, but they can apparently survive on surfaces long enough to be detected in clinical settings. Research on a bird-specific mycoplasma species found that colder temperatures significantly extended the pathogen’s viability on surfaces, with the organism remaining capable of causing disease for up to a week in cold conditions.²⁰ While that study focused on a non-human species, the principle is relevant: cold, dry environments may allow mycoplasma to persist on surfaces longer than warm ones. Hand hygiene and surface cleaning remain sensible precautions during a known outbreak, even though direct person-to-person contact is far more important for transmission.

Reducing Your Risk in Practice

Preventing mycoplasma infection depends entirely on which species you are trying to avoid. For M. pneumoniae, the same measures that reduce your exposure to other respiratory infections apply: good hand hygiene, avoiding close contact with people who have a lingering cough, and ventilating shared indoor spaces. There is no vaccine available for M. pneumoniae, though several candidates are in development. During known outbreaks, the most effective institutional strategy is limiting the number of different people each caregiver or staff member interacts with, rather than broad quarantine measures.¹³

For M. genitalium, consistent condom use is the most practical prevention strategy. Because the infection is frequently asymptomatic, you cannot rely on the absence of symptoms in a partner as reassurance. If you are diagnosed with another STI, asking about mycoplasma testing is reasonable, given the high co-infection rates. Routine screening of the general population for M. genitalium is not currently recommended in most guidelines, partly because of the antibiotic resistance concerns described above and partly because asymptomatic colonization often clears on its own.

For pregnant women, the high rates of vertical transmission mean that awareness is the main tool. If you develop symptoms of genital infection during pregnancy, or if routine screening detects M. hominis or related species, your provider can discuss whether treatment before delivery makes sense for your situation. For most healthy, full-term pregnancies, colonization of the newborn resolves without intervention.